Cabozantinib for liver cancer that returns after liver transplant
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies cabozantinib, a cancer medicine, for liver cancer that has come back after a liver transplant. It’s for people whose cancer can’t be cured with more surgery or local procedures, to see if the treatment can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed hepatocellular carcinoma (a type of liver cancer) that has returned
- You had a prior liver transplant for liver cancer, and the cancer is back afterward
- Your cancer cannot be treated with curative surgery or local procedures, and it can be measured on scans
- You have not taken cabozantinib before (you may have had up to one prior treatment line with sorafenib or lenvatinib)
- You’re age 18 or older, can take pills by mouth, and your general health is good enough for treatment
- Your pregnancy test is negative if you can become pregnant, and you agree to use effective birth control during and for a set time after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
This trial tests whether a combination of chemotherapy (FOLFOX) and a targeted therapy (lenvatinib) can help prevent liver cancer from coming back after a liver transplant. It is for people who meet specific health and medication requirements.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) for people whose liver cancer has returned after a liver transplant and cannot be treated with surgery or other local procedures. The goal is to see if this treatment is safe for liver transplant recipients.
This trial tests whether adding trastuzumab to the standard drug regorafenib works better than regorafenib alone for people with advanced liver cancer that has grown after initial treatment. It is for those who have already received a type of immunotherapy combined with a targeted drug (like atezolizumab + bevacizumab).
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.